Lou Silverman
Known title: DirectorCIK: 0001249935
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
STAAR Surgical Names New VP, Faces High Valuation Questions. STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.
Transaction History
| IMDX | ▼ Sell | Tax Withholding | 7,700 | $44K | 7/1/2026 | View on chart |
| STAA | ▲ Buy | Option Exercise | 10,683 | $0 | 6/18/2026 | View on chart |
| IMDX | ▲ Buy | Grant | 26,943 | $0 | 6/11/2026 | View on chart |
| IMDX | ▲ Buy | Grant | 35,000 | $0 | 7/1/2025 | View on chart |
| IMDX | ▲ Buy | Grant | 25,000 | $0 | 6/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
iMDx Amends Chronix Merger Deal Terms
Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.
iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.